Meunier 1990a.

Methods	Randomised, parallel group study conducted in Belgium. Patient, carer, assessor blind. No clear information on withdrawals given. No information on funding except all study drugs supplied by Pfizer. No dates for recruitment period.
Participants	Adults with mixed cancer. 40 patients enrolled, 37 completed.
Interventions	2 groups. Ketoconazole 2 x 200 mg, once/day. Fluconazole 2 x 250 mg/day. Duration of therapy from 4 to 27 days, median 14 days.
Outcomes	Clinical eradication, and improvement. Assessment made at days 4 to 27. Microbiological eradication of initial pathogen (culture).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Quote: "Randomisation chart".
Allocation concealment?	Low risk	Quote: "All study drugs were supplied by Pfizer and were administered in identical capsules".
Blinding of participants and carers?	Low risk	Quote: "All study drugs were supplied by Pfizer and were administered as identical capsules".
Blinding of outcome assessors?	Low risk	Quote: "....double‐blind".
Incomplete outcome data addressed?	Low risk	Quote: "Forty patients enrolled in the study, 3 were excluded (8%) before the code was opened". Comment: The reasons were given but not by group as the code was not broken. It is felt not to be a source of bias.
Free of selective reporting?	Low risk	Comment: Clinical and mycological eradication (culture).
Free of other biases?	Unclear risk	No information on funding except all study drugs supplied by Pfizer.